Search results
Showing 76 to 90 of 91 results for cholesterol
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)
Evidence-based recommendations on lorlatinib (Lorviqua) for untreated ALK-positive advanced non-small-cell lung cancer in adults.
This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.
Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.
Spiral Flow peripheral vascular graft for treating peripheral arterial disease (MIB34)
NICE has developed a medtech innovation briefing (MIB) on the Spiral Flow peripheral vascular graft for treating peripheral arterial disease
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
CG181/4 | What is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with type 1 diabetes?
Developing NICE guidelines: the manual
Up to 2.1 million people with cardiovascular disease (CVD) could benefit from a new cholesterol target outlined in NICE guidance for the first time.
NICE has today (10 June 2022) published final draft guidance which recommends icosapent ethyl for reducing the risk of cardiovascular events such as heart attacks and strokes in adults who have raised levels of a type of blood fat called triglycerides.
NICE approves ground-breaking cholesterol-lowering drug inclisiran
NICE has today (1 September 2021) issued draft final guidance recommending the novel anti-cholesterol drug inclisiran (Leqvio and made by Novartis) for people with primary hypercholesterolaemia or mixed dyslipidaemia who have already had a cardiovascular event such as a heart attack or stroke.
Annual diabetes checks among indicators proposed for latest NICE QOF menu
A series of annual checks to monitor and improve the health of people with diabetes are among measures proposed by NICE for its latest Quality and Outcomes Framework (QOF) indicator menu.
All eligibility criteria must be met for Liraglutide to be offered
NICE recommend dapagliflozin for people with chronic kidney disease
Dapagliflozin belongs to a group of medicines called ‘sodium glucose co-transporter-2 (SGLT2) inhibitors. It is the first SGLT2 inhibitor to be recommended through NICE’s technology appraisal process for CKD.
NICE publishes its guideline on the diagnosis and management of abdominal aortic aneurysms
NICE has today (19 March 2020) published its guideline on the diagnosis and management of abdominal aortic aneurysms (AAA).
New evidence on the safety of statins means more people could benefit from them, new NICE draft guidance says.